| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pulmatrix, Inc.$1.72
-0.08 (-4.44%)
D 39Pipeline Score Fair Value Pharma · Clinical
Market Cap
4.89 M
EPS
-1.24
P/E Ratio
-
Value Trade
17.58 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.00 K
Operating CF
-1.07 M
Total Assets
4.50 M
Total Liabilities
905.00 K
Equity
3.59 M
D/E Ratio
12,345
6.35 %
Week
-6.29 %
1 Month
-50.37 %
3 Month
-70.61 %
6 Month
-92.72 %
5 Year
-99.97 %
All Time
Cash Data
Cash Position
3.32 M
Monthly Burn
356.00 K
Runway
7.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
46.12 K
52 Week Range
1.16 - 9.37
% held by Insiders
0 %
% held by Institutions
9.02 %
Enterprise Value
1.82 M
Total Shares
3.65 M
Short %
2.8 %
Float Shares
3.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pulmatrix, Inc.
315Total events
6Upcoming
98Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 6
TBD
T2Timing Guidance
Merger financings to support advancement of PTC-2105 through key clinical milestones
TBD
T1Partnership / License
Seeking license or monetization of iSPERSE technology and clinical assets (PUR3100, PUR1800, PUR1900)
TBD
T1Program Discontinuation
Divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900)
Event history 309
Apr 21, 2026
▼Equity OfferingCorporate
Closing of Series B Preferred Stock private placement with Eos affiliate
Mar 2, 2026
2026
▲Trial InitiationPUR1900Trial
Cipla expects to commence Phase 3 trial of PUR1900 in India
fungal infections (ABPA etc.)source ↗
Q1 2026
Dec 18, 2025
Drug Pipeline Intelligence
D39
Pipeline Score $14M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored2.9x
rNPV / MCap Top 54%
Micro Cap (rank 421 of 912)
Percentile RankPulmatrix, Inc. faces pipeline headwinds (39/100), with $1.5B risk-adjusted pipeline value, led by CG001419 in Solid Tumors Harboring NTRK Fusion (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CG001419 Small molecule | Healthy Volunteer Study | Phase 1 | NCT06636500 | 14% | $568M | COMPLETED | 72 | - | - | Dec 5, 2025 | - | Feb 20, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PUR3100 | acute migraine | Phase 1 | 2024-05-15 | Cmax: 3620–14,400; AUC0–2h: 1120–4320; nausea incidence: 21% vs. 86%; vomiting incidence: 0% vs. 29%; headache incidence: 16% vs. 57%; mean time to Cmax: 5 vs. 5.5 min; minimum effective Cmax: 1000 pg/mL Read More | Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) Read More | |
PUR3100 | acute migraine | Phase 1 | 2024-05-15 | Cmax: 3620–14,400; AUC0–2h: 1120–4320; nausea incidence: 21% vs. 86%; vomiting incidence: 0% vs. 29%; headache incidence: 16% vs. 57%; mean time to Cmax: 5 vs. 5.5 min; minimum effective Cmax: 1000 pg/mL Read More | Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) Read More | |
PUR3100 | acute migraine | Phase 1 | 2024-05-15 | Cmax: 3620–14,400; AUC0–2h: 1120–4320; nausea incidence: 21% vs. 86%; vomiting incidence: 0% vs. 29%; headache incidence: 16% vs. 57%; mean time to Cmax: 5 vs. 5.5 min; minimum effective Cmax: 1000 pg/mL Read More | Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PULM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PULM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PULMPulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix, Inc. announced its first quarter 2026 financial results, highlighting a merger agreement with Eos SENOLYTIX and a successful private placement raising $1 million. The company is focusing on monetizing its clinical assets while preparing for a Phase 3 trial of PUR1900 in India. However, it reported a decrease in cash reserves and a net loss of $1.172 million.
Read more →PULMPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Pulmatrix, Inc. has successfully closed a private placement of Series B Convertible Preferred Stock, raising approximately $1 million. This investment, made by an affiliate of Eos SENOLYTIX, is part of Pulmatrix's planned merger with Eos. The funds will be utilized for working capital and general corporate purposes, marking a significant step in the merger process.
Read more →PULM▼ -28.8%on this news· ran to -39% by day 3
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix, Inc. and Eos SENOLYTIX, Inc. have announced a merger agreement to form a combined entity that will operate as Eos SENOLYTIX, targeting aging-related diseases using innovative mitochondrial therapies. The merger is expected to capitalize on $19 million in financing to advance their lead clinical candidate, PTC-2105, aimed at addressing sarcopenia and other age-related conditions. This merger highlights a strategic shift in obesity management, focusing not just on weight loss but on improving overall body composition and healthspan. The transaction has received unanimous approval from both companies' boards and is anticipated to close in mid-2026, pending customary regulatory approvals.
Read more →PULM▼ -36.8%on this news
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix has announced the termination of its merger agreement with Cullgen due to delays in regulatory approval from the China Securities Regulatory Commission. Following this, Pulmatrix is exploring alternative merger opportunities and has reported positive interest in potential transactions. The company remains focused on its development of inhaled therapeutic products.
Read more →PULM▼ -36.8%on this newsshared move
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commiss
Pulmatrix, Inc. has officially announced the termination of its merger agreement with Cullgen, which was halted due to delays from the China Securities Regulatory Commission. Following this development, Pulmatrix is now actively pursuing alternative merger opportunities. The company's interim CEO expressed optimism regarding the interest in potential transactions within the industry. Despite this, the termination introduces challenges and uncertainties related to future mergers and compliance.
Read more →PULM▼ -9.3%on this news· ran to -36% by day 3shared move
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Pulmatrix, Inc. reported its financial results for 2025, revealing a significant drop in revenues to nil. The company is focusing on completing its merger with Cullgen while exploring licensing options for its iSPERSE technology. Despite a decrease in cash reserves, Pulmatrix aims to fund operations into early 2027. The merger's completion is contingent on regulatory approvals.
Read more →PULM▼ -8.1%on this news· ran to -42% by day 3
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix and Cullgen have agreed to waive the "No Solicitation" clause in their merger agreement to explore alternative transactions while continuing to seek regulatory approval from the China Securities Regulatory Commission. Despite stockholder approval and preparation steps, the companies have not yet received necessary final approvals. Pulmatrix's fiscal health appears stable, expecting to fund operations through late 2026. The ongoing clinical development of their inhaled therapeutic products shows potential benefits for migraine and respiratory diseases.
Read more →PULMPulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Pulmatrix, Inc. announced its third quarter 2025 financial results and plans to divest its iSPERSE™ technology and related assets as part of a proposed merger with Cullgen. The merger aims to create a company focused on targeted protein degradation therapies. Financial results indicate a significant decrease in revenues and ongoing operational challenges.
Read more →PULMPulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Pulmatrix, Inc. reported its second quarter 2025 financial results and outlined a divestment plan for its inhalation assets as it prepares for a merger with Cullgen. The merger aims to create a Nasdaq-listed entity focused on targeted protein degradation therapies. Financial results showed a significant decrease in revenues and ongoing operational challenges, including the winding down of clinical trials.
Read more →PULM▲ +6.6%on this news
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Pulmatrix, Inc. announced its first quarter 2025 financial results and a divestment plan for its assets, including the Phase 2-ready acute migraine candidate, PUR3100. The company is in the process of merging with Cullgen, which is expected to close in June 2025. Financial results showed a decrease in revenues to $0, attributed to the completion of the PUR1900 trial. Pulmatrix's cash position is projected to sustain operations through the merger's anticipated closing.
Read more →PULMPulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Pulmatrix, Inc. reported its fourth-quarter and year-end financial results for 2024, highlighting a revenue increase due to a contract modification. The biopharmaceutical company is moving forward with a merger with Cullgen, anticipated to close in the first half of 2025, while planning to divest its clinical assets including the migraine treatment PUR3100. The company has seen a significant decrease in total assets and has incurred financial losses related to earlier transactions, which may affect its operational stability.
Read more →PULM▲ +73.7%on this news· ran to +228% by day 3
Pulmatrix and Cullgen Announce Proposed Merger
Pulmatrix and Cullgen have announced a planned merger that will result in a Nasdaq-listed entity focusing on targeted protein degradation technology. The combined company is expected to have approximately $65 million in cash to support upcoming clinical trials, including those for cancer and pain treatment. Following the merger, the ownership for pre-merger Pulmatrix shareholders will decrease significantly, as they will hold only 3.6% of the new entity. The merger is anticipated to close by the end of March 2025, pending shareholder and regulatory approvals.
Read more →PULMPulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its third quarter 2024 financial results, reporting a decrease in revenues primarily due to the wind down of the PUR1900 Phase 2b clinical trial. The company closed transactions with MannKind Corporation, which validates its iSPERSE™ technology. Despite a decrease in revenues, Pulmatrix projects a cash runway into Q4 2026, allowing for continued operational focus on strategic alternatives for its products.
Read more →PULMPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its second quarter 2024 financial results, highlighting a significant cash reserve that extends its operations into Q4 2026. The company has completed key transactions with MannKind Corporation, reaffirming the potential of its iSPERSE™ technology. Despite a decrease in revenues mainly due to the winding down of the PUR1900 Phase 2b study, Pulmatrix is exploring partnerships to advance its other drug candidates, particularly PUR3100 for acute migraines and PUR1800 for COPD. Positive Phase 1 results for PUR3100 were noted, alongside plans for a Phase 2 clinical study.
Read more →PULMPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix has entered a cross-license agreement with MannKind Corporation, allowing Pulmatrix to use MannKind's Cricket inhalation device for its PUR3100 formulation. MannKind will also assume the lease of Pulmatrix's Bedford R&D facility, enhancing collaboration on future drug development. This partnership aims to advance treatments for acute migraine and other neurological diseases.
Read more →PULMPulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix announced the publication of clinical results for its orally inhaled PUR3100, a formulation of dihydroergotamine for acute migraine treatment. The Phase 1 study demonstrated rapid pharmacokinetics and improved safety compared to intravenous DHE. The company is now preparing for a Phase 2 clinical trial to further explore PUR3100's efficacy.
Read more →PULMPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. reported its first quarter financial results for 2024, showing a revenue increase to $5.9 million and a net income of $0.8 million. The company has amended its partnership with Cipla, leading to the wind down of the PUR1900 Phase 2b study, which will reduce cash burn. Furthermore, Pulmatrix plans to focus on PUR3100, showing promising early trial results and is exploring additional partnerships to support its development pipeline.
Read more →PULM▲ +8%on this news
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its financial results for Q4 and year-end 2023, highlighting a cash balance of $19.2 million projected to last until Q1 2026. The company has decided to wind down the PUR1900 Phase 2b study, transferring development responsibilities to Cipla while earning a small royalty on any future sales. Additionally, Pulmatrix received FDA acceptance for an IND application for PUR3100, prompting a Phase 2 study to investigate its safety and efficacy in migraine treatment. Positive results from past trials suggest progress for Pulmatrix's inhaled therapies amidst financial adjustments.
Read more →PULM▲ +8%on this news
Exhibti 99.1 Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cip
Pulmatrix, Inc. (PULM) announced its financial results for Q4 and the year 2023, reporting a cash position of $19.2 million which provides a runway into Q1 2026. The company is winding down the PUR1900 Phase 2b study to reduce cash burn and is shifting focus to PUR3100, for which the FDA has approved a Phase 2 study. Financially, Pulmatrix recorded a net loss of $14.1 million for the year, despite a revenue increase linked to its partnership with Cipla. The strategy involves minimizing cash expenditure while exploring strategic alternatives for its drug development programs.
Read more →PULMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix, Inc. has announced the cessation of patient enrollment in the Phase 2B study of PUR1900, as part of an agreement with Cipla, which will assume full development responsibility. This decision is strategically aimed at reducing cash burn and allowing Pulmatrix to pursue other alternatives. Pulmatrix retains a cash reserve of approximately $19 million and will earn a 2% royalty on net sales from the product in the Cipla Territory. Although this shift may streamline efforts in markets with high unmet needs, it reflects a significant change in Pulmatrix's operational strategy.
Read more →PULMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives Cipla to take sole resp
Pulmatrix, Inc. has announced the cessation of patient enrollment in its Phase 2B study of PUR1900, in collaboration with Cipla, as part of a strategy to preserve cash and seek alternative directions. Cipla will assume exclusive responsibility for the development of PUR1900, allowing Pulmatrix to concentrate on maximizing shareholder value while reducing its operational costs. As of December 31, 2023, Pulmatrix reported approximately $19 million in cash, which is expected to support the company through early 2026 while it evaluates potential strategic alternatives.
Read more →PULMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its third quarter 2023 financial results, highlighting ongoing patient enrollment for its Phase 2b study of PUR1900 and the receipt of FDA approval for PUR3100's Phase 2 study. The company reported a slight decline in revenues to $1.8 million, but maintains a cash position of $21.3 million projected to last into Q1 2025. The CEO emphasized operational efficiency and plans to advance their clinical programs. The anticipated topline data for PUR1900 is expected in the second half of 2024, showcasing the company's ongoing focus on innovative therapies.
Read more →PULMPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active
Pulmatrix, Inc. reported its second quarter 2023 financial results and updated its ongoing clinical programs. Enrollment for the Phase 2b study of PUR1900 is active with a total of thirteen sites across four countries, with topline data expected in Q3 2024. The company has also submitted an IND for PUR3100 targeting acute migraine, though the initiation of the trial awaits additional funding or partnerships. Pulmatrix anticipates it will have sufficient funds to operate into the first quarter of 2025.
Read more →PULMPulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Pulmatrix, Inc. has submitted an investigational new drug (IND) application to the FDA for PUR3100, an inhaled formulation of dihydroergotamine aimed at treating acute migraines. The submission follows positive results from a Phase 1 trial, which indicated the drug's pharmacokinetics are comparable to intravenous DHE while exhibiting a more favorable safety profile. The Phase 2 trial will focus on the safety and preliminary efficacy of PUR3100 in migraine patients, leveraging Pulmatrix's proprietary iSPERSE technology for effective drug delivery.
Read more →PULMPulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline resul
Pulmatrix, Inc. has announced its financial results for the first quarter of 2023, highlighting the initiation of patient dosing for its Phase 2b study of PUR1900 targeting allergic bronchopulmonary aspergillosis (ABPA). Additionally, the company reported positive topline results from its Phase 1 study of PUR3100 for acute migraine, with plans to advance towards Phase 2 by mid-2023. The firm's financial position includes $30.8 million in cash, projected to sustain operations through Q4 2024, supporting its development pipeline.
Read more →PULMPulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2
Pulmatrix, Inc. reported its financial results for the year and fourth quarter of 2022, highlighting key developments in its drug pipeline. The company reported a net loss of $18.8 million but achieved positive results in its Phase 1 study of PUR3100 and initiated dosing in its Phase 2b study of PUR1900. Additionally, Pulmatrix's CEO expressed optimism regarding progress and milestones in 2023. The company ended 2022 with $35.6 million in cash, providing a runway for operations into Q2 2024.
Read more →PULMPulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Pulmatrix, Inc. has announced the dosing of the first patient in its Phase 2b trial investigating the safety and efficacy of PUR1900, an inhaled formulation targeting Allergic Bronchopulmonary Aspergillosis (ABPA) in asthma patients. This trial is a randomized, double-blind study intended to assess the treatment's efficacy over a 16-week period, followed by an 8-week observation phase. The trial will be conducted across multiple countries, including the US, UK, Australia, and France, aiming to generate proof-of-concept data by mid-2024. PUR1900 could become the first approved treatment for ABPA, offering advantages over existing oral therapies.
Read more →PULM▲ +10.2%on this news
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
Pulmatrix, Inc. announced a virtual key opinion leader webinar focused on its treatment for acute migraine, PUR3100, which uses dihydroergotamine (DHE). The event will feature Dr. Stewart J. Tepper, who will discuss migraine treatment landscapes and the clinical profile of DHE. Dr. Margaret Wasilewski, Pulmatrix’s CMO, will present the latest Phase 1 data and future clinical plans for PUR3100. Currently, there is a significant need for improved migraine treatments, as many existing options do not provide full relief for patients.
Read more →PULM▼ -12.4%on this news
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine PUR3100 was safe and all doses had fewer GI side effects compared to IV
Pulmatrix, Inc. announced positive top line results from a Phase 1 trial of PUR3100, an orally inhaled formulation of dihydroergotamine (DHE) for acute migraine treatment. The trial demonstrated that PUR3100 was safe and well-tolerated, with fewer gastrointestinal side effects than intravenous DHE. Additionally, peak exposure levels were achieved within the therapeutic range for all doses tested. Pulmatrix plans to seek FDA consultation as it enters the next phase of development for PUR3100.
Read more →PULMPulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.
Announces Third Quarter 2022 Financial Results and Provides Corporate Update (Pulmazole) on track for Phase 2 study start in Q1 2023 Phase 1 study top line data anticipated in early Q1 2023 million in cash and cash equivalents at end of Q3 2022 Mass., November 10, 2022 - Pulm
Read more →PULMPulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine Company is evaluating its iSPERSE TM orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of
Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine is evaluating its iSPERSETM orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4
Read more →PULMPulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update is on track for Phase 2b study start in Q1 2023 Phase 1 study is underway with data anticipated in Q4 2022 Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass., August 8,
Read more →PULMPulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study
Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study Mass., July 12, 2022 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage
Read more →PULMPulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024
Announces First Quarter 2022 Financial Results and Provides Corporate Update Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 Mass., May 12, 2022 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovati
Read more →PULMPulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update Mass., March 29, 2022 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using
Read more →PULMPulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable
Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD Mass., March 21, 2022 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease usi
Read more →PULMPulmatrix Regains Compliance With Nasdaq Listing Requirements
Regains Compliance With Nasdaq Listing Requirements Mass., March 17, 2022 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE tech
Read more →PULM▼ -7.4%on this news
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline Mass., March 1, 2022 /PRNewswire/ - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary d
Read more →PULMPulmatrix, Inc. Announces 1-for-20 Reverse Stock Split
Inc. Announces 1-for-20 Reverse Stock Split Mass., February 24, 2022 - Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using i
Read more →PULMPulmatrix Announces Closing of $6.75 Million Registered Direct Offering
Announces Closing of $6.75 Million Registered Direct Offering Mass., December 17, 2021 /PRNewswire/ - Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary a
Read more →PULM▼ -31.6%on this newsshared move
Pulmatrix Announces $6.75 Million Registered Direct Offering
Announces $6.75 Million Registered Direct Offering Mass., December 15, 2021 (GLOBE NEWSWIRE) - Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non
Read more →PULMPulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmazole contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspe
Reports Third Quarter 2021 Financial Results and Provides Business Update contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) (Acute Migraine Product) IND submission planned for Q1 2022 Ph1
Read more →PULMPulmatrix Announces Resolution of Contract Dispute with Cipla
Announces Resolution of Contract Dispute with Cipla Mass., November 9, 2021 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE tec
Read more →PULMPulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022 PUR1800 6-month rat and 9-month dog toxicology data may enabl
Reports Second Quarter 2021 Financial Results and Provides Business Update Phase 1b study is fully enrolled with data anticipated in Q1 2022 6-month rat and 9-month dog toxicology data may enable expansion to chronic conditions Phase 1/ Phase 2 clinical study in acute migraine
Read more →PULMLEXINGTON, Mass.
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ - Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, today announced the a
Read more →PULMPulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in
Reports First Quarter 2021 Financial Results and Provides Business Update Phase 1b data anticipated in Q4 2021 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 runway extends beyond anticipated PUR1800 Ph1b and PUR3100 Ph1/Ph2 data m
Read more →PULMCorrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Termination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnso
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to continue development of PUR1800 for treatment of Acute
Read more →PULMPulmatrix Reports 2020 Financial Results and Provides Business Update Initiated PUR1800 Phase 1b study with data anticipated in Q4 2021 Pulmazole Ph2b study start anticipated Q1 2022 PUR3100 development candidate declare
Reports 2020 Financial Results and Provides Business Update PUR1800 Phase 1b study with data anticipated in Q4 2021 Ph2b study start anticipated Q1 2022 development candidate declared for pulmonary delivered DHE (dihydroergotamine) acute migraine treatment runway extends beyo
Read more →PULMPulmatrix Reports Third Quarter 2020 Financial Results and Business Updates Focused pipeline with multiple potential clinical and regulatory milestones in 2021 Pulmatrix to receive escalating royalties from partner Senso
Reports Third Quarter 2020 Financial Results and Business Updates pipeline with multiple potential clinical and regulatory milestones in 2021 to receive escalating royalties from partner Sensory Cloud upon sales of FEND, OTC nasal hygiene product proven to reduce airborne resp
Read more →PULMPulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles Pulmatrix's Partner Sensory Cloud to Conduct World
Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles Partner Sensory Cloud to Conduct Worldwide Marketing Distribution to Receive Escalating Royalties upon Commencement o
Read more →PULMPulmatrix Announces Changes to Board of Directors
Announces Changes to Board of Directors Mass., June 26, 2020 / PRNewswire/ - Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE technology,
Read more →PULMPulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19
Pulmatrix and Sensory Cloud Announce Partnership to Develop and a Potential Nasal Prophylactic and Anticontagion Product for COVID-19 LEXINGTON, Mass., April 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovativ
Read more →PULMPulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules LEXINGTON, MA
Announces $8.0 Million Registered Direct Offering At-the-Market under Nasdaq Rules MA, April 16, 2020 - Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease usi
Read more →PULMExecution Version
Hayden Avenue, Suite 390 Teofilo Raad, Chief Executive Officer Dear letter agreement (this "Agreement") constitutes the agreement between Pulmatrix, Inc. (the "Company") and H.C. Wainwright & Co., LLC ("Wainwright"), that Wainwright shall serve as the exclusive agent, advisor
Read more →PULMPulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA LEXINGTON, Mass., January 30, 2020 /PRNewswire/ Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900
Read more →PULMThis presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated b
PULMATRIX Corporate Overview Exhibit This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated benefits or other cons
Read more →PULMSafe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or a
PULMATRIX Corporate Overview I NASDAQ: Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated benefits
Read more →PULMPulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole TM Transaction marks Cipla s entry into specialty respiratory segment, building on inroads made
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of PulmazoleTM Lexington, Mass.; April 15, 2019: Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as Pulmatrix ), a clinical stage biopharmaceutical company focus
Read more →PULMPulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering Underwriter Exercises In Full Option to Purchase Additional Securities
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering Underwriter Exercises In Full Option to Purchase Additional Securities LEXINGTON, Mass., April 8, 2019 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announc
Read more →PULMPulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering LEXINGTON, Mass., April 3, 2019 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announced the pricing of its previously announced underwritten public offering
Read more →PULMPulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole The Binding Term Sheet Executed on
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole The Binding Term Sheet Executed on April 1, 2019 Lays Groundwork for Entry into a Definitive Agreement During the 2nd Quarter of 2019 LEXINGTON, MA Pulm
Read more →PULMPulmatrix, Inc. Announces Closing of Public Offering of Common Stock
Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock LEXINGTON, Mass., February 5, 2019 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public
Read more →PULMPulmatrix, Inc. Announces Proposed Public Offering of Common Stock
Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock LEXINGTON, Mass., January 30, 2019 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announced that it intends to offer and sell, subject to market and other conditions,
Read more →PULMPULMATRIX ANNOUNCES $3.0
PULMATRIX ANNOUNCES $3.0 MILLION REGISTERED DIRECT OFFERING LEXINGTON, Mass., November 29, 2018 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional i
Read more →PULMPULMATRIX ANNOUNCES PRICING OF $15.2
PULMATRIX ANNOUNCES PRICING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING LEXINGTON, Mass., March 29, 2018 /PRNewswire/ Pulmatrix, Inc. ( Pulmatrix, the Company, we, our or us ) (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,
Read more →PULMSafe Harbor This presentation contains forward-looking statements. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipates," "assumes," "believes," "can," "could," "estimates
PULMATRIX Corporate Overview February 2018 NASDAQ: PULM Exhibit 99.1 Safe Harbor This presentation contains forward-looking statements. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipates," "assumes," "believes," "can," "could,
Read more →PULMCEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months
Dr. Robert Clarke, CEO of Pulmatrix, discussed recent partnerships and developments during an interview. The collaboration with Vectura focuses on the drug candidate PUR0200 for COPD, with Vectura covering development costs. Additionally, Pulmatrix's PUR1800 shows promise for treating COPD exacerbations, while PUR1900 targets fungal infections in severe asthma and cystic fibrosis patients.
Read more →PULMDisclaimers & Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipates," "assumes," "believes
Engineering Respiratory Products for Major Unmet Pulmonary Diseases September 2017 NASDAQ: PULM Exhibit 99.1 Disclaimers & Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements may be identified by the use of forward-looki
Read more →PULMPulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc The agreement will accelerate the development of the innovative inhaled drug LEXINGTON, MA Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceuti
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc The agreement will accelerate the development of the innovative inhaled drug LEXINGTON, MA Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to add
Read more →PULMAmit D. Munshi Joins Pulmatrix s Board of Directors Mr. Munshi brings over 25 years of executive leadership experience in biotechnology and pharmaceuticals to help Pulmatrix move through the next stage of company develop
Amit D. Munshi Joins Pulmatrix s Board of Directors Mr. Munshi brings over 25 years of executive leadership experience in biotechnology and pharmaceuticals to help Pulmatrix move through the next stage of company development. LEXINGTON, MA Pulmatrix, Inc. (NASDAQ: PULM), a pha
Read more →PULMPulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc. The novel compounds target an enzyme involved in both inflammation and cancer, and may offer a new approach
Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen The novel compounds target an enzyme involved in both inflammation and cancer, and may offer a new approach for treating respiratory diseases LEXINGTON, MA Pulmatrix, Inc. (NASDA
Read more →PULMPulmatrix Announces Over $3.0 Million Registered Direct Offering
Pulmatrix Announces Over $3.0 Million Registered Direct Offering LEXINGTON, Mass., Feb. 3, 2017 /PRNewswire/ Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announce
Read more →PULMPULMATRIX ANNOUNCES $5
PULMATRIX ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING LEXINGTON, Mass., Jan. 30, 2017 - Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has ent
Read more →PULMPulmatrix Reports Third Quarter 2016 Financial Results and Business Update
Pulmatrix Reports Third Quarter 2016 Financial Results and Business Update LEXINGTON, Mass., Nov. 4, 2016 /PRNewswire/ Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today
Read more →PULMPulmatrix Reports Q2 2016 Financial Results
Pulmatrix Reports Q2 2016 Financial Results LEXINGTON, Mass., August 4, 2016 /PRNewswire/ Pulmatrix, Inc. (NASDAQ:PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline. In the first half of the year, we
Read more →PULMPulmatrix and Mylan Report Positive Pharmacokinetic Bioavailability Data in Pilot Study of PUR0200 in Patients with Chronic Obstructive Pulmonary Disease (COPD) Data Support Continued Development Towards Pivotal Bioequiv
Pulmatrix and Mylan Report Positive Pharmacokinetic Bioavailability Data in Pilot Study of PUR0200 in Patients with Chronic Obstructive Pulmonary Disease Data Support Continued Development Towards Pivotal Bioequivalence Program for European Registration Improved Efficiency of D
Read more →PULMPulmatrix, Inc. (Nasdaq: PULM) to Ring the Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Pulmatrix, Inc. (Nasdaq:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Robert
Read more →PULMPulmatrix Appoints Mark Iwicki Chairman of the Board
LEXINGTON, Mass., Dec. 8, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of directors. Terry McGuire, who has served as ch
Read more →PULMBIO Investor Conference
BIO Investor Conference October 20, 2015 Robert Clarke, Ph.D. President & Chief Executive Officer NASDAQ: PULM Engineering the Future for Inhaled Therapeutics 2 Disclaimers & Forward Looking Statements This presentation contains forward - looking statements . Forward - looking s
Read more →PULMVirtual Investor Conference
Virtual Investor Conference August 6, 2015 Robert Clarke, Ph.D. President & Chief Executive Officer NASDAQ: PULM Engineering the Future for Inhaled Therapeutics 2 Forward Looking Statements Disclaimers and Forward Looking Statements This presentation contains forward - looking s
Read more →PULMPulmatrix Appoints William Duke, Jr., as Chief Financial Officer Lexington, Mass.
Pulmatrix Appoints William Duke, Jr., as Chief Financial Officer Lexington, Mass., June 25, 2015 - Pulmatrix, Inc. (NASDAQ: PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valerit
Read more →PULMLEXINGTON, Mass. and HERTFORDSHIRE, England and PITTSBURGH
LEXINGTON, Mass. and HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 -- Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. develop
Read more →PULMPulmatrix Raises $10 Million Private Placement; To Begin Trading on NASDAQ under "PULM" Pulmatrix, Inc. now has $27 million in cash and cash equivalents LEXINGTON, MA
Raises $10 Million Private Placement; Trading on NASDAQ under "PULM" Inc. now has $27 million in cash and cash equivalents MA - June 16, 2015 - Pulmatrix, Inc., (NASDAQ: PULM), previously known as Ruthigen, Inc., today announced the completion of its previously announced merg
Read more →PULMRuthigen and Pulmatrix Stockholders Approve Merger SANTA ROSA, CA and LEXINGTON, MA
Ruthigen and Pulmatrix Stockholders SANTA ROSA, CA and LEXINGTON, MA-June 12, 2015-Ruthigen, Inc. ("Ruthigen") (NASDAQ: RTGN) and Pulmatrix Inc. ("Pulmatrix") today announced that at Ruthigen's special meeting of stockholders held on June 12, 2015, Ruthigen obtained sufficient
Read more →PULMRuthigen Reports Fiscal Second Quarter 2015 Financial Results To Host Conference Call at 4:30 P.M. EST on Thursday
Ruthigen Reports Fiscal Second Quarter 2015 Financial Results To Host Conference Call at 4:30 P.M. EST on Thursday, Nov. 13, 2014 SANTA ROSA, Calif., Nov. 13, 2014 /PRNewswire/ -- Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal second quarter 2015
Read more →PULMRuthigen Reports Fiscal First Quarter 2015 Financial Results SANTA ROSA, Calif. - (
Ruthigen Reports Fiscal First Quarter 2015 Financial Results SANTA ROSA, Calif. - (August 14, 2014) - Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal first quarter 2015 ended June 30, 2014. Fiscal First Quarter 2015 Financial Results As of June 3
Read more →PULMRuthigen Reports Fourth Quarter and Fiscal Year 2014 Financial Results SANTA ROSA, Calif. - (
Ruthigen Reports Fourth Quarter and Fiscal Year 2014 Financial Results SANTA ROSA, Calif. - (June 30, 2014) - Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fourth quarter and fiscal year ended March 31, 2014. "We are poised to commence patient enrollme
Read more →PULMRuthigen Announces Pricing of Initial Public Offering Santa Rosa, CA
Ruthigen Announces Pricing of Initial Santa Rosa, CA - March 21, 2014 - Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical-grade hypochlorous acid, or HOCl, based therapeutics designed to pr
Read more →Competitive Position
How PULM ranks across every disease it competes inCompetitive Position is a premium feature
See how PULM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial